Comparative efficacy of modified FOLFIRINOX, gemcitabine plus capecitabine and gemcitabine plus nab-paclitaxel as adjuvant treatment for resected pancreatic cancer: a Bayeasian network meta-analysis
Victor Hugo Fonseca de Jesus and Rachel P Riechelmann
ecancer 15 1276 (2021) https://doi.org/10.3332/ecancer.2021.1276
Medical Oncology Department, A.C. Camargo Cancer Center, Rua Prof. Antônio Prudente 211, São Paulo SP 01509-010, Brazil
Throughout the text, please consider that the primary outcome of the PRODIGE24 trial was disease-free survival, and not overall survival.
Keywords: FOLFIRINOX, gemcitabine, capecitabine, nab-paclitaxel, adjuvant, pancreatic, cancer
Correspondence to: Victor Hugo Fonseca de Jesus
Email: victor.jesus@accamargo.org.br
Published: 12/10/2021
Received: 23/09/2021
Publication costs for this article were supported by ecancer (UK Charity number 1176307).
Copyright: © the authors; licensee ecancermedicalscience. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Funding source
This study had no funding source.
Authors’ contributions
Victor Hugo Fonseca de Jesus: conceptualisation, methodology, data curation, data analyses, writing and visualisation; Rachel Pimenta Riechelmann: methodology, writing and visualisation.
